Phaseline

Targets › CNR2

CNR2 (Cannabinoid receptor 2): drug programs, companies and trials

42 programs from 29 companies in 54 trials: 32 Phase 1, 19 Phase 2, 2 Phase 3, 1 Phase 4; Psychiatry, Neurology, Other; next expected readout Nov 2026.

Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis. (UniProt, P34972)

Open in Phaseline: the race on CNR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alasht PharmedCanvert-M
Topical cannabidiol with essential oils (peppermint, lavender, rosemary, eucalyptus, winte
CNR1, CNR2Phase 4Migraine Disorders–
University of Colorado, DenverTHC/CBD
Cannabinoid receptor agonist (THC and CBD)
CNR1, CNR2Phase 3Back PainJun 2027
VertanicalVER-01
Cannabis sativa extract containing Δ9-tetrahydrocannabinol (THC) - cannabinoid receptor ag
CNR1, CNR2Phase 3Lumbosacral RadiculopathySep 2028
IGC PharmaIGC-AD1
Delta-9-tetrahydrocannabinol (THC)
CNR1, CNR2Phase 2Alzheimer DiseaseNov 2026
University of ManitobaMPL-001
Cannabidiol-enriched cannabis with THC 2 mg/ml and CBD 50 mg/ml; targets cannabinoid recep
CNR1, CNR2Phase 2Chronic Migraine; Childhood CancerDec 2026
Federal University of Latin American IntegrationOral Cannabis Extract (Full-Spectrum)
Cannabinoid CB1 and CB2 receptor agonist
CNR1, CNR2Phase 2Psoriasis Vulgaris; Alzheimer Disease (AD)Feb 2027
BC Centre on Substance UseAurora 1:1 Drops (Indica)
Combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 1:1 ratio
CNR1, CNR2Phase 2Opioid Use DisorderMar 2027
Incannex HealthcareIHL-42X
Dronabinol (cannabinoid CB1/CB2 receptor agonist) combined with acetazolamide (carbonic an
CNR1, CNR2, CA2Phase 2Obstructive Sleep Apnea (OSA)Apr 2027
University Medical Center GroningenMedical Cannabis Oil
Cannabinoid mixture containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
CNR1, CNR2Phase 2Hepatocellular CarcinomaApr 2027
Brown UniversityCBD-dominant cannabis
Cannabinoid receptor modulator (CBD-dominant preparation with 0.35% THC and 11.27% CBD)
CNR1, CNR2Phase 2Alcohol DrinkingAug 2027
Brown UniversityTHC-dominant cannabis
Cannabinoid CB1 and CB2 receptor agonist (THC-dominant preparation with 9.53% THC and 0.09
CNR1, CNR2Phase 2Alcohol DrinkingAug 2027
Southwest Autism Research & Resource CenterMB-IMP
CBD (cannabidiol) and THC (tetrahydrocannabinol) mixture; CBD is a non-selective cannabino
CNR1, CNR2Phase 2Autism Spectrum DisorderSep 2027
Bazelet NehushtanTerpenes-Enriched CBD-Predominant Oil (T1/C28)
Cannabinoid system modulation with CBD and minor THC with terpenes
CNR1, CNR2Phase 2AutismDec 2027
Yale UniversityCBD 300mg (Nantheia™ ATL5 300mg)
Cannabidiol - cannabinoid receptor modulator
CNR1, CNR2Phase 2Chronic PainJan 2028
VA Office of Research and DevelopmentTHC (Syndros)
Cannabinoid receptor agonist (CB1 and CB2)
CNR1, CNR2Phase 2Neuropathic PainSep 2028
VA Office of Research and DevelopmentTHC + CBD (Nabiximols)
Combination cannabinoid receptor agonist (CB1 and CB2) plus cannabidiol
CNR1, CNR2Phase 2Neuropathic PainSep 2028
University of CalgaryCBD 200 mg OD
Cannabinoid receptor agonist
CNR1, CNR2Phase 2Chronic MigraineDec 2028
NeuroTherapiaNTRX-07
CB2 agonist
CNR2Phase 2Alzheimer Disease–
Zynerba PharmaceuticalsZYN002
Cannabidiol transdermal gel
CNR1, CNR2Phase 2Fragile X Syndrome–
Murdoch Childrens Research InstituteC12T12 Ruby Balanced Oil
Cannabinoid mixture containing THC and CBD
CNR1, CNR2Phase 1Palliative CareNov 2026
Murdoch Childrens Research InstituteC20T5 Ruby CBD Oil
Cannabinoid mixture containing CBD and THC
CNR1, CNR2Phase 1Palliative CareNov 2026
University of California, Los AngelesVaporized Beta-Caryophyllene (0.5 mg)
Cannabinoid CB1/CB2 receptor agonist
CNR1, CNR2Phase 1PainNov 2026
University of California, Los AngelesCBG (Cannabigerol)
Cannabinoid receptor agonist
CNR1, CNR2Phase 1PainDec 2026
University of California, Los AngelesTHC (Tetrahydrocannabinol)
Cannabinoid receptor agonist
CNR1, CNR2Phase 1PainDec 2026
Yale UniversityDelta-9-THC Very Low Dose
Cannabinoid CB1 and CB2 receptor agonist
CNR1, CNR2Phase 1Cannabis; Age-related Cognitive Decline; SchizophreniaDec 2026
Universidade do Sul de Santa CatarinaFull-spectrum CBG oil 30 mg/mL
Full-spectrum Cannabis extract containing cannabigerol (CBG), cannabidiol (CBD), and tetra
CNR1, CNR2, GPR55Phase 1Attention-Deficit/Hyperactivity Disorder (ADHD)Dec 2026
Florida A&M UniversityFull-Spectrum CBD hemp extract oral solution
Cannabinoid-rich botanical extract with multi-target anti-inflammatory and neuroprotective
CNR1, CNR2Phase 1Diabetic Peripheral Neuropathic Pain (DPN)Dec 2026
Universidade do Sul de Santa CatarinaFull-spectrum CBD oil 100 mg/mL
Cannabidiol (CBD) and tetrahydrocannabinol (THC) from Cannabis sativa extract; CBD is a no
CNR1, CNR2Phase 1Major Depressive Disorder (MDD)Dec 2026
University of ManitobaMPL-005
Cannabidiol-enriched cannabis herbal extract (1:5 THC:CBD ratio)
CNR1, CNR2Phase 1Childhood CancerDec 2026
University of ManitobaMPL-009
Balanced cannabis herbal extract (1:1 THC:CBD ratio)
CNR1, CNR2Phase 1Childhood CancerDec 2026
University of California, Los AngelesTHC + CBD
Combination of cannabinoid receptor agonist (THC) and cannabinoid receptor modulator (CBD)
CNR1, CNR2Phase 1Drug AbuseJun 2027
Shanna Babalonis, PhDInhaled vaporized cannabis
Cannabinoid receptor agonist (low THC formulation)
CNR1, CNR2Phase 1Opioid Use Disorder; CancerJun 2027
University of California, Los AngelesCBD 40 mg
Cannabinoid receptor modulator; non-competitive antagonist at CB1
CNR1, CNR2Phase 1Abuse, DrugSep 2027
University of California, Los AngelesCBD 80 mg
Cannabinoid receptor modulator; non-competitive antagonist at CB1
CNR1, CNR2Phase 1Abuse, DrugSep 2027
Washington State UniversityTHC 20mg
Cannabinoid receptor agonist
CNR1, CNR2Phase 1Cannabis UseMay 2028
Staci Gruber, Ph.D.Custom-formulated, high-CBD study product
Full-spectrum hemp-derived high-CBD product
CNR1, CNR2Phase 1EndometriosisJan 2029
Johns Hopkins UniversityTHC 5mg
Cannabinoid CB1/CB2 receptor agonist
CNR1, CNR2Phase 1Cannabis UseApr 2029
Johns Hopkins UniversityTHC Low Dose
Cannabinoid receptor agonist
CNR1, CNR2Phase 1Cannabis UseApr 2029
Milton S. Hershey Medical CenterCBG/CBD Oil
Cannabinoid receptor agonist (CBG/CBD blend with CBC)
CNR1, CNR2Phase 1Chemotherapy-Induced Peripheral NeuropathyApr 2029
University of California, San DiegoBRC-002
Cannabidiolic acid (CBDA) and CBD with minor cannabinoids
CNR1, CNR2Phase 1Complex Regional Pain SyndromeJun 2029
University of British ColumbiaCannabis oil with a high ratio of THC to CBD
Cannabinoid receptor agonist (THC-dominant)
CNR1, CNR2Phase 1Healthy–
McMaster UniversityTetrahydrocannabinol (THC)
Partial agonist of cannabinoid receptors CB1 and CB2
CNR1, CNR2Phase 1Cannabis–

Conditions

Pain (4) Cannabis Use (3) Cannabis (3) Childhood Cancer (3) Cancer (3) Alzheimer Disease (2) Alcohol Drinking (2) Opioid Use Disorder (2) Abuse, Drug (2) Psoriasis Vulgaris (2) Chronic Migraine (2) Neuropathic Pain (2)

Modalities

small molecule (41)

Companies

University of California, Los Angeles (6) University of Manitoba (3) Brown University (2) Johns Hopkins University (2) Universidade do Sul de Santa Catarina (2) VA Office of Research and Development (2) Yale University (2) Murdoch Childrens Research Institute (2) IGC Pharma (1) BC Centre on Substance Use (1) Zynerba Pharmaceuticals (1) Florida A&M University (1) Federal University of Latin American Integration (1) University of Colorado, Denver (1) Southwest Autism Research & Resource Center (1) Washington State University (1) Milton S. Hershey Medical Center (1) University of British Columbia (1) University of Calgary (1) McMaster University (1)

Related targets

CNR1 (41) GPR55 (1) CA2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.